Senior Correspondent, London
Ben's Feed
Oct 23, 2014
Oct 23, 2014

Fixing ‘Ebolanomics’ in pursuit of vaccines and drugs

LONDON (Reuters) – As researchers from Africa to China to America race to develop vaccines and treatments to fight Ebola, health experts are grappling with the economics of a disease that until this year had been off the drug industry’s radar.

Whether or not effective drugs come in time to turn around the world’s worst epidemic of the virus ravaging three West African countries, the world will want stockpiles to protect against inevitable future outbreaks, experts say.

Oct 23, 2014
Oct 23, 2014

Drugmakers may need indemnity for fast-tracked Ebola vaccines

LONDON/GENEVA (Reuters) – Drugmakers are looking for some kind of indemnity from governments or multilateral agencies for the widespread emergency use of new Ebola vaccines in Africa.

While the issue will not delay the industry’s ongoing work to accelerate production and clinical testing of three experimental vaccines, it is likely to be discussed at a high-level meeting in Geneva on Thursday.

Oct 22, 2014

Exclusive – EU earmarks $250 million to help develop Ebola vaccines: sources

LONDON (Reuters) – Europe is to plough 200 million euros (155.5 million pounds) into the development of Ebola vaccines, as well as drugs and diagnostic tests, according to two people with direct knowledge of the situation.

The funding is set to be announced this week under the Innovative Medicines Initiative (IMI), a public-private scheme jointly paid for by the pharmaceuticals industry and the European Commission.

Oct 22, 2014

EU earmarks $250 million to help develop Ebola vaccines: sources

LONDON (Reuters) – Europe is to plow 200 million euros ($250 million) into the development of Ebola vaccines, as well as drugs and diagnostic tests, according to two people with direct knowledge of the situation.

The funding is set to be announced this week under the Innovative Medicines Initiative (IMI), a public-private scheme jointly paid for by the pharmaceuticals industry and the European Commission.

Oct 22, 2014
Oct 22, 2014

GSK eyes top slot in FTSE 100 index for standalone HIV drugs unit

LONDON, Oct 22 (Reuters) – GlaxoSmithKline, battered
by weak U.S. drug sales and a bribery scandal in China, set out
a bold recovery plan on Wednesday, including an initial public
offering of part of its fast-growing HIV and AIDS drugs
business.

As a standalone company ViiV Healthcare would be among the
top 40 companies in London’s FTSE 100 index, outranking such
household names as retailer Marks and Spencer, GSK Chief
Executive Andrew Witty told reporters.

Oct 22, 2014

Drugmakers to join forces to make millions of Ebola vaccine doses

LONDON (Reuters) – Leading drugmakers plan to work together to accelerate development of an Ebola vaccine and produce millions of doses of the most effective experimental product for use next year.

Johnson & Johnson (JNJ.N: Quote, Profile, Research) said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain’s GlaxoSmithKline (GSK.L: Quote, Profile, Research), which is working on a rival vaccine.

Oct 22, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben